Shares of Kenvue Inc.
KVUE,
+3.64%
gained nearly 5% Tuesday morning after a federal court’s ruling in a product-liability case appeared to work in the Tylenol maker’s favor. The case involves multiple product-liability lawsuits, now consolidated in a New York federal court, filed against the manufacturers of Tylenol and generic acetaminophen and alleging that in-utero exposure to the drug caused children to develop autism spectrum disorder and attention-deficit hyperactivity disorder.
Judge Denise Cote of U.S. District Court for the Southern District of New York on Monday granted the defendants’ motion to exclude plaintiffs’ expert opinions on whether in-utero exposure to acetaminophen could cause the autism and attention-deficit disorders. The scientific evidence on prenatal use of acetaminophen “presents a challenge for any expert witness offering the opinion that such use causes” the disorders, Cote wrote in her opinion. The Food and Drug Administration, Cote noted, has evaluated the risks at issue in the case multiple times and has not found a causal link between acetaminophen and neurodevelopmental disorders. The court’s ruling “is a clean sweep for the defendants,” J.P. Morgan analysts wrote in a research note Monday, adding that the ruling “effectively collapses the plaintiffs’ case in the multi-district litigation.” Kenvue, the consume …
Article Attribution | Read More at Article Source
KVUE,
+3.64%
gained nearly 5% Tuesday morning after a federal court’s ruling in a product-liability case appeared to work in the Tylenol maker’s favor. The case involves multiple product-liability lawsuits, now consolidated in a New York federal court, filed against the manufacturers of Tylenol and generic acetaminophen and alleging that in-utero exposure to the drug caused children to develop autism spectrum disorder and attention-deficit hyperactivity disorder.
Judge Denise Cote of U.S. District Court for the Southern District of New York on Monday granted the defendants’ motion to exclude plaintiffs’ expert opinions on whether in-utero exposure to acetaminophen could cause the autism and attention-deficit disorders. The scientific evidence on prenatal use of acetaminophen “presents a challenge for any expert witness offering the opinion that such use causes” the disorders, Cote wrote in her opinion. The Food and Drug Administration, Cote noted, has evaluated the risks at issue in the case multiple times and has not found a causal link between acetaminophen and neurodevelopmental disorders. The court’s ruling “is a clean sweep for the defendants,” J.P. Morgan analysts wrote in a research note Monday, adding that the ruling “effectively collapses the plaintiffs’ case in the multi-district litigation.” Kenvue, the consume …nnDiscussion:nn” ai_name=”RocketNews AI: ” start_sentence=”Can I tell you more about this article?” text_input_placeholder=”Type ‘Yes'”]